Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

Status Completed

Clinical Trial Summary

Vitamin D deficiency is very common in patients with fatty liver disease as evidenced by our observations in the Metabolic Liver Clinic and that reported by others. We also observed that patients with more severe fatty liver disease had lower Vitamin D concentrations. Others have shown that replacing Vitamin D in patients with cirrhosis is effective and even patients with Vitamin D replete status have lowering of Vitamin D over time if not supplemented.

One of the measures of liver injury in NAFLD is the plasma concentration of ALT and we will use this to follow patients as is currently done as standard of care. All patients in the Metabolic Liver Clinic are being routinely screened for Vitamin D deficiency as standard of care and treatment is being started with oral supplementation, but there are not standardized protocols to determine success of therapy. We hypothesize that patients with NAFLD with low Vitamin D levels will respond appropriately to Vitamin D supplementation for 6 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver

Clinical Trial Details

NCT number	NCT03084328
Study type	Observational
Source	The Cleveland Clinic
Contact
Status	Completed
Phase	N/A
Start date	January 20, 2012
Completion date	March 10, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04031729` - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease	Phase 1/Phase 2
Recruiting	`NCT03725631` - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD	N/A
Active, not recruiting	`NCT05084404` - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease	Phase 2
Completed	`NCT05081427` - Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
Recruiting	`NCT05430178` - Metabolic Pathology of Pediatric NAFLD	N/A
Recruiting	`NCT04389593` - Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference
Active, not recruiting	`NCT05199948` - Weight, Energy, Lipids, and the Liver (WELL) Study	N/A
Active, not recruiting	`NCT03696797` - Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease	N/A
Terminated	`NCT02365233` - Fatty Liver Study in Patients With Type II Diabetes	Phase 4
Completed	`NCT05309642` - Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study	N/A
Completed	`NCT03763877` - A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD	Phase 2
Not yet recruiting	`NCT06335771` - Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity	N/A
Completed	`NCT04828551` - Noninvasive Biomarkers of Metabolic Liver Disease 1.1	N/A
Recruiting	`NCT05792423` - Conditionally Increased Output (CIO) Enhanced Ultrasound System	N/A
Recruiting	`NCT02815891` - A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Not yet recruiting	`NCT05908877` - Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Not yet recruiting	`NCT04887766` - Study on GS300 on NAFLD	N/A
Completed	`NCT03986684` - Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Recruiting	`NCT05165706` - Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance	N/A
Completed	`NCT04235205` - Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease	Phase 2